INVA Live-Signale | Maximieren Sie Profite mit Getagraph.com

VERKAUFEN 107864 min ago

@ $15.84

Ausgestellt: 14 Feb 2024 @ 21:17

Rendite: -2.53%

Vorheriges Signal: Feb 14 - 19:26

Vorheriges Signal: Kaufen

Rendite: 0.54 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 20:00):

Stats
Tagesvolumen	154 618
Durchschnittsvolumen	701 717
Marktkapitalisierung	976.23M
EPS	$0 ( 2024-02-27 )
Nächstes Ertragsdatum	( $0.170 ) 2024-05-07
Last Dividend	$0.250 ( 2015-09-08 )
Next Dividend	$0 ( N/A )
P/E	7.02
ATR14	$0.00800 (0.05%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-05	Basso Stephen	Buy	25 899	Non-statutory Stock Option
2024-03-05	Basso Stephen	Buy	12 096	Common Stock
2024-03-05	Ronsheim Matthew	Buy	27 338	Non-statutory Stock Option
2024-03-05	Ronsheim Matthew	Buy	12 768	Common Stock
2024-03-05	Zhen Marianne	Buy	23 022	Non-statutory Stock Option

INSIDER POWER
89.73
Last 96 transactions
Buy: 2 118 652 \| Sell: 32 343 813

Volumen Korrelation

Lang: 0.15 (neutral)

Kurz: 0.08 (neutral)

Signal:(55.257) Neutral

Innoviva Inc Korrelation

10 Am meisten positiv korreliert
ESSA	0.92
ONEM	0.92
NAKD	0.911
AADI	0.909
AROW	0.908
DSWL	0.906
CMLS	0.906
AZTA	0.905
BSRR	0.904
UK	0.902

10 Am meisten negativ korreliert
NEO	-0.927
TMDX	-0.919
XLRN	-0.916
MORF	-0.916
HAPP	-0.915
SVC	-0.914
ACVA	-0.913
SGTX	-0.911
MHUA	-0.909
SJ	-0.909

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Innoviva Inc Korrelation - Währung/Rohstoff

-0.53
( weak negative )

-0.56
( weak negative )

0.00
( neutral )

0.02
( neutral )

-0.74
( moderate negative )

0.71
( moderate )

Innoviva Inc Finanzdaten

Annual	2023
Umsatz:	$324.26M
Bruttogewinn:	$245.92M (75.84 %)
EPS:	$-1.910

FY	2023
Umsatz:	$324.26M
Bruttogewinn:	$245.92M (75.84 %)
EPS:	$-1.910

FY	2022
Umsatz:	$331.34M
Bruttogewinn:	$317.55M (95.84 %)
EPS:	$-1.080

FY	2021
Umsatz:	$391.87M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$2.62

Financial Reports:

No articles found.

Innoviva Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Innoviva Inc Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.08 - Potential for dividend initiation, but uncertain (1.64%)

Information

First Dividend	$0.250	2014-08-26
Last Dividend	$0.250	2015-09-08
Next Dividend	$0	N/A
Payout Date	2015-09-30
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	$1.250	--
Avg. Dividend % Per Year	0.00%	--
Score	3.98	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.08
Div. Directional Score	8.09	--

Next Divdend (Est)
(2024-06-19)

$0 Estimate 0.00 %

Dividend Stability

0.03 Very Bad

Dividend Score

3.98

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2014	$0.500	1.84%
2015	$0.750	5.65%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.573	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	0.145	1.200	5.18	6.22	[0 - 0.3]
returnOnEquityTTM	0.297	1.500	7.81	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	9.03	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	7.28	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	5.07	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.360	-1.500	4.00	-6.00	[0 - 0.6]
interestCoverageTTM	9.70	1.000	7.52	7.52	[3 - 30]
operatingCashFlowPerShareTTM	2.21	2.00	9.26	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.21	2.00	8.90	10.00	[0 - 20]
debtEquityRatioTTM	0.663	-1.500	7.35	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.832	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.592	1.000	0.162	0.162	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.315	1.000	9.36	9.36	[0.2 - 2]
assetTurnoverTTM	0.252	0.800	-1.650	-1.320	[0.5 - 2]
Total Score				11.10

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	5.41	1.000	9.55	0	[1 - 100]
returnOnEquityTTM	0.297	2.50	8.59	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.21	2.00	9.26	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.21	2.00	9.26	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.531	1.500	9.79	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.449	1.000	1.265	0	[0.1 - 0.5]
Total Score				5.08

Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.